Estimating the cost savings due to the effect of kremezin in delaying the initiation of dialysis treatments among patients with chronic renal failure

Hye Young Kang, Woohyun Cho, Sunmi Lee, Hyung Jong Kim, Ho Yong Lee, Tae Wook Woo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives : We wanted to evaluate the economic value of a pharmaceutical product, Kremezin, for treating patients with chronic renal failure (CRF) by estimating the amount of cost savings due to its effect for delaying the initiation of dialysis treatments. Methods : We defined a conventional treatment for CRF accompanied by Kremezin therapy as 'the treatment group' and only conventional treatment as 'the alternative group.' The types of costs included were direct medical and non-medical costs and costs of productivity loss. The information on the effect of Kremezin was obtained from the results of earlier clinical studies. Cost information was derived from the administrative data for 20 hemodialysis and 20 peritoneal dialysis patients from one tertiary care hospital, and also from the administrative data of 10 hemodialysis patients from one free-standing dialysis center. Per-capita cost savings resulting from Kremezin therapy were separately estimated for the cases with delay for the onset of hemodialysis and the cases with immediate performance of peritoneal dialysis. By computing the weighted average for the cases of hemodialysis and peritoneal dialysis, the expected per-capita cost savings of a patient with CRF was obtained. Using a discount rate of 5%, future cost savings were converted to the present value. Results : The present value of cumulative cost savings per patient with CRF from the societal perspective would be 18,555,000-29,410,000 Won or 72,104,000-112,523,000 Won if Kremezin delays the initiation of dialysis by 1 or 4 years. Conclusions : The estimated amount of cost savings resulting from treating CRF patients with Kremezin confirms that its effect for delaying the onset of dialysis treatments has a considerable economic value.

Original languageEnglish
Pages (from-to)149-158
Number of pages10
JournalJournal of Preventive Medicine and Public Health
Volume39
Issue number2
Publication statusPublished - 2006 Mar 1

Fingerprint

Cost Savings
Chronic Kidney Failure
Dialysis
Renal Dialysis
Peritoneal Dialysis
Costs and Cost Analysis
Therapeutics
Economics
Tertiary Healthcare
AST 120
Tertiary Care Centers
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

@article{9be8e057fe9f4ae0b48aa9ff9fc5dc89,
title = "Estimating the cost savings due to the effect of kremezin in delaying the initiation of dialysis treatments among patients with chronic renal failure",
abstract = "Objectives : We wanted to evaluate the economic value of a pharmaceutical product, Kremezin, for treating patients with chronic renal failure (CRF) by estimating the amount of cost savings due to its effect for delaying the initiation of dialysis treatments. Methods : We defined a conventional treatment for CRF accompanied by Kremezin therapy as 'the treatment group' and only conventional treatment as 'the alternative group.' The types of costs included were direct medical and non-medical costs and costs of productivity loss. The information on the effect of Kremezin was obtained from the results of earlier clinical studies. Cost information was derived from the administrative data for 20 hemodialysis and 20 peritoneal dialysis patients from one tertiary care hospital, and also from the administrative data of 10 hemodialysis patients from one free-standing dialysis center. Per-capita cost savings resulting from Kremezin therapy were separately estimated for the cases with delay for the onset of hemodialysis and the cases with immediate performance of peritoneal dialysis. By computing the weighted average for the cases of hemodialysis and peritoneal dialysis, the expected per-capita cost savings of a patient with CRF was obtained. Using a discount rate of 5{\%}, future cost savings were converted to the present value. Results : The present value of cumulative cost savings per patient with CRF from the societal perspective would be 18,555,000-29,410,000 Won or 72,104,000-112,523,000 Won if Kremezin delays the initiation of dialysis by 1 or 4 years. Conclusions : The estimated amount of cost savings resulting from treating CRF patients with Kremezin confirms that its effect for delaying the onset of dialysis treatments has a considerable economic value.",
author = "Kang, {Hye Young} and Woohyun Cho and Sunmi Lee and Kim, {Hyung Jong} and Lee, {Ho Yong} and Woo, {Tae Wook}",
year = "2006",
month = "3",
day = "1",
language = "English",
volume = "39",
pages = "149--158",
journal = "Journal of Preventive Medicine and Public Health",
issn = "1975-8375",
publisher = "Korean Society for Preventive Medicine",
number = "2",

}

Estimating the cost savings due to the effect of kremezin in delaying the initiation of dialysis treatments among patients with chronic renal failure. / Kang, Hye Young; Cho, Woohyun; Lee, Sunmi; Kim, Hyung Jong; Lee, Ho Yong; Woo, Tae Wook.

In: Journal of Preventive Medicine and Public Health, Vol. 39, No. 2, 01.03.2006, p. 149-158.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Estimating the cost savings due to the effect of kremezin in delaying the initiation of dialysis treatments among patients with chronic renal failure

AU - Kang, Hye Young

AU - Cho, Woohyun

AU - Lee, Sunmi

AU - Kim, Hyung Jong

AU - Lee, Ho Yong

AU - Woo, Tae Wook

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Objectives : We wanted to evaluate the economic value of a pharmaceutical product, Kremezin, for treating patients with chronic renal failure (CRF) by estimating the amount of cost savings due to its effect for delaying the initiation of dialysis treatments. Methods : We defined a conventional treatment for CRF accompanied by Kremezin therapy as 'the treatment group' and only conventional treatment as 'the alternative group.' The types of costs included were direct medical and non-medical costs and costs of productivity loss. The information on the effect of Kremezin was obtained from the results of earlier clinical studies. Cost information was derived from the administrative data for 20 hemodialysis and 20 peritoneal dialysis patients from one tertiary care hospital, and also from the administrative data of 10 hemodialysis patients from one free-standing dialysis center. Per-capita cost savings resulting from Kremezin therapy were separately estimated for the cases with delay for the onset of hemodialysis and the cases with immediate performance of peritoneal dialysis. By computing the weighted average for the cases of hemodialysis and peritoneal dialysis, the expected per-capita cost savings of a patient with CRF was obtained. Using a discount rate of 5%, future cost savings were converted to the present value. Results : The present value of cumulative cost savings per patient with CRF from the societal perspective would be 18,555,000-29,410,000 Won or 72,104,000-112,523,000 Won if Kremezin delays the initiation of dialysis by 1 or 4 years. Conclusions : The estimated amount of cost savings resulting from treating CRF patients with Kremezin confirms that its effect for delaying the onset of dialysis treatments has a considerable economic value.

AB - Objectives : We wanted to evaluate the economic value of a pharmaceutical product, Kremezin, for treating patients with chronic renal failure (CRF) by estimating the amount of cost savings due to its effect for delaying the initiation of dialysis treatments. Methods : We defined a conventional treatment for CRF accompanied by Kremezin therapy as 'the treatment group' and only conventional treatment as 'the alternative group.' The types of costs included were direct medical and non-medical costs and costs of productivity loss. The information on the effect of Kremezin was obtained from the results of earlier clinical studies. Cost information was derived from the administrative data for 20 hemodialysis and 20 peritoneal dialysis patients from one tertiary care hospital, and also from the administrative data of 10 hemodialysis patients from one free-standing dialysis center. Per-capita cost savings resulting from Kremezin therapy were separately estimated for the cases with delay for the onset of hemodialysis and the cases with immediate performance of peritoneal dialysis. By computing the weighted average for the cases of hemodialysis and peritoneal dialysis, the expected per-capita cost savings of a patient with CRF was obtained. Using a discount rate of 5%, future cost savings were converted to the present value. Results : The present value of cumulative cost savings per patient with CRF from the societal perspective would be 18,555,000-29,410,000 Won or 72,104,000-112,523,000 Won if Kremezin delays the initiation of dialysis by 1 or 4 years. Conclusions : The estimated amount of cost savings resulting from treating CRF patients with Kremezin confirms that its effect for delaying the onset of dialysis treatments has a considerable economic value.

UR - http://www.scopus.com/inward/record.url?scp=33646342982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646342982&partnerID=8YFLogxK

M3 - Article

C2 - 16615270

AN - SCOPUS:33646342982

VL - 39

SP - 149

EP - 158

JO - Journal of Preventive Medicine and Public Health

JF - Journal of Preventive Medicine and Public Health

SN - 1975-8375

IS - 2

ER -